Prosiectau (339)
Cardiff University Schools involved in this Project
T1D-Plus: a clinical trial platform for combined beta cell preservation therapy (01.09.2022 - 31.08.2026)
- Dayan, Colin
T1D-Plus: An adaptive trial platform for the study of combination therapies in new-onset T1D (01.12.2023 - 30.11.2026)
- Dayan, Colin
T1D UK Clinical Trials consortium - mechanistic core (01.01.2015 - 05.12.2021)
- Wong, Susan
T1D UK Immunotherapy Consortium: Clinical Engagement and Training (CET) Core (01.05.2015 - 30.03.2020)
- Dayan, Colin
TACTICC study (01.06.2015 - 31.12.2016)
- Godkin, Andrew
Take home naloxone Intervention Multi centre Emergency setting feasibility trial (TIME) (01.03.2018 - 31.08.2020)
- Edwards, Adrian
- Taking imaging into the therapeutic domain: self-regulation of brain systems for mental disorders
(01.11.2013 - 31.10.2018)- Linden, David
Talking about HPV related cancer: Development and testing of scripted consultations (01.07.2014 - 30.06.2016)
- Adams, Richard
Talking Trials: Exploration of clinical trial perceptions amongst BAME communities (01.04.2020 - 31.03.2022)
- Svobodova, Martina
Talking Trials: Participatory approaches to creating community dialogue (01.10.2022 - 31.01.2024)
- Svobodova, Martina
TAP Centre (01.01.2020 - 31.12.2022)
- Knapper, Steven
TAPERS study Excess Treatment Costs (01.10.2018 - 31.01.2022)
- Hall, Jeremy
Targeted stabilisation of human cardiac ryanodine receptors as a therapeutic strategy for cardiac disease (01.10.2009 - 30.09.2014)
- George, Christopher
Targeted vaccines for infectious disease and cancer (01.04.2010 - 30.09.2010)
- Sewell, Andrew
Targeted vaccines for infectious disease and cancer (31.03.2010 - 30.09.2012)
- Sewell, Andrew
Targeting alpha-beta - crystalline (CRYAB): A novel strategy to impede triple-negative breast cancer development (01.07.2014 - 31.01.2016)
- Cai, Jun
Targeting CD8 using “blocking anti CD8 antibodies” as a strategy to disable autoreactive CD8+ T-cells in Type 1 diabetes (01.01.2023 - 29.02.2024)
- Pearson, James
Targeting CLL cell survival and proliferation with bioactive cell penetrating peptides (01.10.2010 - 30.04.2014)
- Brennan, Paul
Targeting complement to treat fatty liver disease (01.10.2022 - 30.09.2025)
- Zhou, You
Targeting ERK signalling to emeliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2 (01.11.2019 - 31.10.2025)
- Hall, Jeremy
Targeting glucose metabolism for the treatment of Birt Hogg Dube Syndrome (01.10.2009 - 30.09.2010)
- Tee, Andrew
Targeting islet-specific CD8 Tcells in Type 1 diabetes (01.06.2015 - 31.01.2019)
- Wong, Susan
Targeting neuroinflammation in mTORC1 driven brain tumours (01.10.2019 - 31.05.2023)
- Tee, Andrew
Targeting NF-xB activation and proliferation signals in CLL (01.11.2013 - 31.07.2018)
- Pepper, Christopher
- Targeting novel anti-complement drugs to the brain for therapy of
dementia. (01.10.2021 - 31.12.2026)- Zelek, Wioleta